John C Krauss
Clinical Associate Professor of Internal Medicine and Program Director, Regional Cancer Programs
Hematology/Oncology
1500 East Medical Center Dr
Ann Arbor, MI 48109
[email protected]

Available to mentor
John C Krauss
Clinical Associate Professor
  • About
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
    • About

    I am the medical director of the multidisciplinary colorectal clinic, and I actively lead therapeutic clinical trials at the University of Michigan. I work with the Southwest Oncology Group, the NSABP Foundation, and pharmaceutical sponsors to make promising clinical trials available for my patients. I am actively working on eliminating surgery for selected patients with rectal cancer. I am interested in improving communication with my patients so they can get the optimum care for complex conditions.

    Qualifications
    • Hematology/Oncology Fellow
      University of Michigan Medical School, Internal Medicine, 1992
    • Internal Medicine Resident
      University of Minnesota Medical School, Internal Medicine, 1988
    • MD
      University of Michigan, Ann Arbor, 1985
    Center Memberships
    • Center Member
      Rogel Cancer Center
    • Center Member
      Precision Health Initiative
    Research Overview

    The major focus of my research is experimental therapeutics of cancer. I have enrolled patients in FDA registration trials of irinotecan, nab-paclitaxel, regorafenib, and I have been the site principal investigator on the FDA registration trials of entrectinib, and NTRK and ROS1 inhibitor, sotorasib, a KRASG12c inhibitor, and fruquintinib, a VEGF inhibitor. I was the site principal investigator on the organ preservation of rectal cancer trial, which demonstrated that giving combined modality chemotherapy radiation therapy prior to systemic treatment improves the complete response rate of the tumor, so fewer patients need to have an operation.

    Recent Publications See All Publications
    • Journal Article
      Home-based aerobic exercise feasibility in oxaliplatin-receiving newly-diagnosed cancer survivors.
      Kanzawa-Lee GA, Larson JL, Resnicow K, Ploutz-Snyder R, Krauss JC, Smith EML. Eur J Oncol Nurs, 2024 Aug; 71: 102649 DOI:10.1016/j.ejon.2024.102649
      PMID: 38954929
    • Journal Article
      Treatment Modalities for Locally Recurrent Rectal Cancer: A Review
      Regan S, Hendren S, Krauss J, Crysler O, Cuneo K. The Cancer Journal: The Journal of Principles & Practice of Oncology, 2024 Jul 24;
    • Journal Article
      Endoscopic Predictors of Residual Tumor After Total Neoadjuvant Therapy: A Post Hoc Analysis From the Organ Preservation in Rectal Adenocarcinoma Trial.
      Williams H, Thompson HM, Lin ST, Verheij FS, Omer DM, Qin L-X, Garcia-Aguilar J, OPRA Consortium . Dis Colon Rectum, 2024 Mar 1; 67 (3): 369 - 376. DOI:10.1097/DCR.0000000000003096
      PMID: 38039292
    • Presentation
      Next Generation Tumor Sequencing for Personalized Cancer Care
      2024 Feb 20;
    • Journal Article
      Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial.
      Verheij FS, Omer DM, Williams H, Lin ST, Qin L-X, Buckley JT, Thompson HM, Yuval JB, Kim JK, Dunne RF, Marcet J, Cataldo P, Polite B, Herzig DO, Liska D, Oommen S, Friel CM, Ternent C, Coveler AL, Hunt S, Gregory A, Varma MG, Bello BL, Carmichael JC, Krauss J, Gleisner A, Guillem JG, Temple L, Goodman KA, Segal NH, Cercek A, Yaeger R, Nash GM, Widmar M, Wei IH, Pappou EP, Weiser MR, Paty PB, Smith JJ, Wu AJ, Gollub MJ, Saltz LB, Garcia-Aguilar J. J Clin Oncol, 2024 Feb 10; 42 (5): 500 - 506. DOI:10.1200/JCO.23.01208
      PMID: 37883738
    • Proceeding / Abstract / Poster
      Changes in circulating immune biomarkers following nivolumab with or without ipilimumab for metastatic anal cancer (NCI9673).
      Morris VK, Ochieng J, Ciombor KK, Polite BN, Mukherjee S, Krauss JC, Shields AF, Aranha O, Hays JL, Kazmi SMA, Weinberg BA, Benson AB, Lieu CH, Iqbal S, Hochster HS, Xiao L, Haymaker CL, Eng C. Journal of Clinical Oncology, 2024 Jan 20; 42 (3_suppl): 3 - 3. DOI:10.1200/jco.2024.42.3_suppl.3
    • Journal Article
      Enhancing precision: A predictive model for 177Lu-DOTATATE treatment response in neuroendocrine tumors using quantitative 68Ga-DOTATATE PET and clinicopathological biomarkers.
      Akhavanallaf A, Joshi S, Mohan A, Worden FP, Krauss JC, Zaidi H, Frey K, Suresh K, Dewaraja YK, Wong KK. Theranostics, 2024 14 (9): 3708 - 3718. DOI:10.7150/thno.98053
      PMID: 38948061
    • Journal Article
      Exploring Chemotherapy-Induced Peripheral Neuropathy Management Practice Patterns Among Oncology Clinicians.
      Kanzawa-Lee G, Krauss JC, Knoerl R. Semin Oncol Nurs, 2024 Jun 26; 151685 DOI:10.1016/j.soncn.2024.151685
      PMID: 38937199